India, April 28 -- Pfizer Inc. (PFE) on Tuesday said it has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla over patent litigation related to Vyndamax, its treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Under the agreements, the effective U.S. patent expiry for Vyndamax has been extended to June 1, 2031, subject to ongoing litigation outcomes. Pfizer had earlier expected a revenue decline beginning in 2029 due to patent expiry, but now anticipates relatively stable U.S. sales from 2028 through mid-2031.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Vyndamax remains the market leader in ATTR-CM treatment, accounting for about 75% of prescript...